高效毕赤酵母表达载体的改造与应用
- 格式:pdf
- 大小:3.65 MB
- 文档页数:5
毕赤酵母表达实验手册作者:Jnuxz 来源:丁香园时间:2007-9-5大肠杆菌表达系统最突出的优点是工艺简单、产量高、周期短、生产成本低。
然而,许多蛋白质在翻译后,需经过翻译后的修饰加工,如磷酸化、糖基化、酰胺化及蛋白酶水解等过程才能转化成活性形式。
大肠杆菌缺少上述加工机制,不适合用于表达结构复杂的蛋白质。
另外,蛋白质的活性还依赖于形成正确的二硫键并折叠成高级结构,在大肠杆菌中表达的蛋白质往往不能进行正确的折叠,是以包含体状态存在。
包含体的形成虽然简化了产物的纯化,但不利于产物的活性,为了得到有活性的蛋白,就需要进行变性溶解及复性等操作,这一过程比较繁琐,同时增加了成本。
大肠杆菌是用得最多、研究最成熟的基因工程表达系统,当前已商业化的基因工程产品大多是通过大肠杆菌表达的,其主要优点是成本低、产量高、易于操作。
但大肠杆菌是原核生物,不具有真核生物的基因表达调控机制和蛋白质的加工修饰能力,其产物往住形成没有活性的包涵体,需要经过变性、复性等处理,才能应用。
近年来,以酵母作为工程菌表达外源蛋白日益引起重视,原因是与大肠杆菌相比,酵母是低等真核生物,除了具有细胞生长快,易于培养,遗传操作简单等原核生物的特点外,又具有真核生物时表达的蛋白质进行正确加工,修饰,合理的空间折叠等功能,非常有利于真核基因的表达,能有效克服大肠杆菌系统缺乏蛋白翻译后加工、修饰的不足。
因此酵母表达系统受到越来越多的重视和利用。
[1]。
同时与大肠杆菌相比,作为单细胞真核生物的酵母菌具有比较完备的基因表达调控机制和对表达产物的加工修饰能力。
酿酒酵母(Saccharomyces.Cerevisiae)在分子遗传学方面被人们的认识最早,也是最先作为外源基因表达的酵母宿主。
1981年酿酒酵母表达了第一个外源基因----干扰素基因[2],随后又有一系列外源基因在该系统得到表达[3、4、5、6]。
干扰素和胰岛素虽然已经利用酿酒酵母大量生产并被广泛应用,当利用酿酒酵母制备时,实验室的结果很令人鼓舞,但由实验室扩展到工业规模时,其产量迅速下降。
利用强效可调控启动子AOX,已高效表达了HBsAg、TNF、EGF、破伤风毒素C片段、基因1工程抗体等多种外源基因[11、12、13],证实该系统为高效、实用、简便,以提高表达量并保持产物生物学活性为突出特征的外源基因表达系统,而且非常适宜扩大为工业规模[14]11. 彭毅,杨希才,康良仪。
影响甲醇酵母外源蛋白表达的因素。
生物技术通报2000,4:33-3612. 11 3 Cregg JM . Tschopp JF Stillman C, et al .High-level expression and efficient assembly of hepatitis B surface antigen in the methylotrophic yeast pichia.pastoris Bio/Technology,1987,5:479-48513. Sreekrishma K , Nelles L ,Potenz R,et al .High-level expression ,purification ,and characterization of recombinant human tumor necrosis factor synthesized and characterization in the methylotrophic yeast pichia .pastoris ,Biochemistry ,1989,28:4117-412514. Siegel RS , Buckholz RG, Thill GP , et al .Production of epider growth factor in methylotrophic yeast cells, International Patent Application ,1990 ,Publication No:WO90/10697毕赤酵母是甲醇营养型酵母,可利用甲醇作为其唯一碳源。
一、概述乳铁蛋白是一种存在于哺乳动物乳汁中的重要蛋白质,具有丰富的营养价值和生物活性。
其在免疫调节、抗氧化、抗菌、抗病毒等方面具有重要作用,因此受到了广泛的关注。
而毕赤酵母是一种常见的真菌微生物,可以被用于多种重要蛋白的表达和生产。
构建一种强化乳铁蛋白表达的毕赤酵母具有重要的研究意义和应用价值。
二、毕赤酵母的特点1. 毕赤酵母的生物学特性毕赤酵母(Pichia pastoris)是一种酵母,通过改良的形态和工程学技术,可以高效表达和分泌异源蛋白,其优点包括a. 生长速度快b. 表达异源蛋白能力强c. 分泌蛋白质的能力优秀2. 毕赤酵母在蛋白表达中的应用毕赤酵母在蛋白表达中应用广泛,主要包括医药、工业、生物学等领域。
通过毕赤酵母表达系统,可以实现对多种重要蛋白的高效表达和大规模生产。
三、强化乳铁蛋白表达的毕赤酵母构建方法1. 选择适合的毕赤酵母表达载体通过对不同毕赤酵母表达载体的筛选和比较,选取适合乳铁蛋白表达的载体。
2. 乳铁蛋白基因的克隆和插入通过PCR扩增、酶切、连接等分子生物学技术,得到乳铁蛋白基因的重组表达载体。
3. 转化和筛选将表达载体转化至毕赤酵母菌株中,进行筛选得到高效表达乳铁蛋白的毕赤酵母菌株。
4. 条件优化与表达通过调节培养基、温度、pH值等条件,优化乳铁蛋白的表达条件,提高其表达量和纯度。
四、强化乳铁蛋白表达的毕赤酵母的研究进展1. 表达量和纯度的提高通过使用不同的表达载体、优化表达条件等手段,可以显著提高乳铁蛋白的表达量和纯度,满足不同应用的需求。
2. 抗性因子的引入引入抗性因子可以提高毕赤酵母对特定抗生素的抗性,从而提高其在生产中的稳定性和可操作性。
3. 结构与功能分析通过结构生物学等技术手段对乳铁蛋白在毕赤酵母中的结构和功能进行深入研究,为其应用提供理论基础。
五、强化乳铁蛋白表达的毕赤酵母在食品、医药等领域的应用1. 食品领域强化乳铁蛋白表达的毕赤酵母可以用于生产高营养价值的乳制品,如乳粉、奶酪等,提高其抗菌、抗氧化等功能。
毕赤酵母表达蛋白步骤一、引言毕赤酵母(Pichia pastoris)是一种常用的真菌表达系统,被广泛应用于蛋白质的表达和生物技术研究中。
其优势包括高表达水平、易于培养和操作、能够正确折叠复杂蛋白等。
本文将介绍毕赤酵母表达蛋白的步骤。
二、构建表达载体毕赤酵母表达系统的关键是表达载体的构建。
首先,需要选择适合的表达载体,常用的有pPIC6、pPICZα等。
然后,在载体上选择合适的启动子和信号序列,以确保蛋白质能够被正确表达和分泌。
同时,还需要在表达载体上加入选择标记,如His标签、FLAG标签等,以便后续的蛋白质纯化和检测。
三、转化毕赤酵母将构建好的表达载体转化入毕赤酵母中,使其成为表达宿主。
转化方法包括电击转化、化学转化等。
其中,电击转化是常用的方法,通过电击脉冲使毕赤酵母细胞膜发生破裂,使表达载体进入细胞内。
转化后,将细胞培养在选择性培养基上,筛选出带有表达载体的毕赤酵母克隆。
四、表达蛋白经过转化筛选后,得到含有目标蛋白表达载体的毕赤酵母克隆。
接下来,需要将克隆进行培养,在适当的条件下诱导蛋白的表达。
常用的诱导剂包括甲醇、巯基乙醇等,通过加入适量的诱导剂,可以使目标蛋白得到高效表达。
五、蛋白纯化在蛋白表达后,需要进行蛋白纯化,以获得纯度较高的目标蛋白。
常用的纯化方法包括亲和层析、离子交换层析、凝胶过滤层析等。
在选择纯化方法时,需要根据目标蛋白的性质和需求进行合理选择。
同时,可以利用加入的选择标记,如His标签,通过亲和层析纯化进行快速高效的纯化。
六、蛋白鉴定和功能分析蛋白纯化后,需要进行蛋白的鉴定和功能分析。
常用的鉴定方法包括SDS-PAGE、Western blot等,可以确定蛋白的分子量和纯度。
功能分析则可以通过生物学实验来进行,如酶活测定、结合实验等,以验证目标蛋白的功能。
七、应用和展望毕赤酵母表达系统在生物技术和蛋白质研究领域有着广泛的应用。
通过该系统,可以高效表达各种蛋白,包括抗体、酶和重组蛋白等。
毕赤酵母常用培养基与载体一、毕赤酵母表达常用载体:典型的巴斯德毕赤酵母表达载体载体包含醇氧化酶-1(AOX1)基因的启动子和转录终止子(5'AOX1和3'AOX1),它们被多克隆位点(MCS)分开,外源基因可以在此插入。
此载体还包含组氨醇脱氢酶基因(HIS4)选择标记及3'AOX1区。
当整合型载体转化受体时,它的5'AOX1和3'AOX1能与染色体上的同源基因重组,从而使整个载体连同外源基因插入到受体染色体上,外源基因在5'AOX1启动子控制下表达。
毕赤酵母本身不分泌内源蛋白,而外源蛋白的分泌需要具有引导分泌的信号序列。
而由89个氨基酸组成的酿酒酵母的分泌信号—α交配因子(α-factor)引导序列已经成功地引导了几种外源蛋白的分泌。
分泌表达载体主要有:pPIC9,pPIC9K,pHIL-S1,pPICZα A,pYAM75P等。
胞内表达载体主要有:pHIL-D2,pA0815,pPIC3K,pPICZ,pHWO10,pGAPZ,pGAPZa(Invitrogen),pPIC3.5K等。
工程菌株Y11430,MG1003,GS115 (AOX1),KM71,SMD1168。
毕赤酵母宿主菌常用的有GS115和KM71两种,都具有HIS4营养缺陷标记。
其中,GS115茵株具有AOX1基因,是Mut+,即甲醇利用正常型;而KM71菌株的AOX1位点彼ARG4基因插入,表型为Muts,即甲醇利用缓慢型,两种菌株都适用于一般的酵母转化方法。
多拷贝表达菌株的获得方式:与自主复制的质粒型表达载体不同,整合型表达载体的拷贝数可以有很大的变化。
含多拷贝外源基因的表达菌株合成蛋白的量也较多。
体内整合可通过高遗传霉素抗性,筛选可能的多拷贝插入;而体外整合可通过连接产生外源基因的串联插入。
多拷贝表达菌株的获得方式有两种:一种是利用SDS-PAGE电泳、免疫杂交或菌落点杂交方法在大量的转化子中进行自然筛选。
毕赤酵母基因组编辑技术原理基于Red同源重组和CRISPR/Cas9的毕赤酵母基因组编辑服务。
成熟的毕赤酵母(Pichia pastoris)编辑体系,助您成功实现基因敲除、基因插入和点突变。
基于Red同源重组法的毕赤酵母基因组改造毕赤酵母基因敲除的传统方法是利用自身的Red系统对外源进入的DNA进行同源重组,从而实现目标基因的等位替换。
通过设计靶基因的同源融合片段,将其克隆至自杀载体中,自杀载体通过接合输入到靶细菌。
通过抗生素筛选细菌基因组靶位点整合有自杀载体的插入突变株。
在第二轮反向选择压力下,只有毕赤酵母基因组发生第二次同源重组并丢失自杀质粒才可以存活。
基于CRISPR/Cas9平台的毕赤酵母基因组改造CRISPR/Cas9系统是细菌和古细菌特有的一种天然防御系统,用于抵抗病毒或外源性质粒的侵害。
研究内容•毕赤酵母基因敲除(Pichia pastoris gene knockout)•毕赤酵母基因敲入(Pichia pastoris gene knockin)•毕赤酵母基因点突变(Pichia pastoris gene point mutation)下游应用•抗生素及重要工业用酶•发现新的基因功能•优化代谢通路,提升代谢产物产量,实现工业化生产参考文献:•Selle K, Barrangou R. Harnessing CRISPR–Cas systems for bacterial genome editing[J]. Trends in microbiology, 2015, 23(4): 225-232.•Zerbini, F., Zanella, I., Fraccascia, D., König, E., Irene, C., & Frattini, L. F., et al. (2017). Large scale validation of an efficient CRISPR/Cas-based multi gene editing protocol in Escherichia coli.Microbial Cell Factories, 16(1), 68.。
毕⾚酵母表达系统使⽤⼼得Pichia酵母表达系统使⽤⼼得甲醇酵母表达系统有不少优点,其中以Invitrogen公司的Pichia酵母表达系统最为⼈熟知,并⼴泛应⽤于外源蛋⽩的表达。
虽然说酵母表达操作简单表达量⾼,但是在实际操作中,并不是每个外源基因都能顺利得到⾼表达的。
不少⼈在操作中会遇到这样那样的问题,收集了部分⽤户在使⽤EasySelect Pichia Expression System这个被誉为最简单的毕⾚酵母表达的经典试剂盒过程中的⼼得体会。
其中Xiang Yang是来⾃美国乔治城⼤学(Georgetown University)Lombardi癌症中⼼(Lombardi Cancer Center),部分⽤户来⾃国内。
+ 表⽰优胜于;- 表⽰不如;= 表⽰差不多EasySelect Pichia Expression System产品性能:优点——使⽤简单,表达量⾼,His-tag便于纯化缺点——酵母表达蛋⽩有时会出现蛋⽩切割问题全⾯产品报告及⼼得体会:巴斯德毕⾚酵母(Pichia pastoris )是⼀种能⾼效表达重组蛋⽩的酵母品种,⼀⽅⾯由于其是属于真核⽣物,因此表达出来的蛋⽩可以进⾏糖基化修饰,另⼀⽅⾯毕⾚酵母⽣长速度快,可以将表达的蛋⽩分泌到培养基中,⽅便蛋⽩纯化。
毕⾚酵母表达载体pPICZ 在多克隆位点(MCR )3'端带有his-tag 和c-myc epitopes ,这些tag 有利于常规检测和纯化,⽽且在MCR5'端引⼊了alpha factor (α-factor )⽤以增加表达,并且在表达后α-factor 可以⾃动被切除。
在进⾏克隆的时候,如果你选择的是EcoRI ,那么只需在⽬标蛋⽩中增加两个氨基酸序列即可完成。
另外pPICZ 系列选⽤的是Zeocin 抗⽣素作为筛选标记,⽽诱导表达的载体需要甲醇——甲醇⽐⼀般⽤于⼤肠杆菌表达诱导使⽤的IPTG 便宜。
毕赤酵母表达系统前言:所用表达质粒有pPIC3.5K,pAO815用于胞内表达,而pPIC9K用于分泌表达,所有载体均利用AOX1启动子来诱导高水平表达。
抗性选择:最有效的筛选遗传霉素抗性及高抗性克隆的程序需要先对HIS+转化子进行选择,再进行不同水平遗传霉素抗性筛选。
毕赤菌株表型:毕赤酵母菌GS115 及KM71 在组氨酸脱氢酶位点(His4)有突变,因而不能合成组氨酸,所有表达质粒都有HIS4 基因可与宿主进行互补,通过不含组氨酸的培养基来选择转化子。
GS115 及KM71都可在复合培养基如YPD(YEPD)及含组氨酸的最小培养基中生长。
转化之前,GS115 及KM71 都不能在最小培养基中生长,因为它们是His-。
培养温度:毕赤酵母生长温度为28-30度(液体、平板、斜面)。
在32 度以上诱导生长时,对蛋白表达有害,甚至会导致细胞死亡。
贮存:贮存细胞几周或几月,用YPD培养基或YPD 琼脂斜面1 挑取所需菌株单克隆在YPD 平板上划线生长;2 挑取单克隆转移至YPD进行穿刺培养,30 度2 天;3 细胞在4 度可放几周几月或几年,存于-80度1 挑取所需菌株单克隆在YPD 中过夜培养;2 收集细胞,在含15%甘油的YPD 中悬浮至终OD600 为50-100(大约2.5-5.0×109细胞/ml);3 细胞先用液氮或干冰/酒精浴中冰冻再贮存于-80 度。
注意:在4 度或-80 度长期保存后,用之前建议在MM、MD 或MGY 平板上划线培养以检测His+转化子的表型是否正确及其活力。
以质粒pPIC9K,酵母Pichia pastoris GS115为例说明做法。
载体pPIC9K酶切为点线性化质粒DNA:建议使用下列方法线性化载体以获得Mut+及Muts重组子,可能其中一个会比另一个更利于表达多拷贝重组子。
如果只想得到Muts重组子,使用KM71 菌株。
单个十字交换事件可比双重十字交换更容易、更有效地获得Muts重组菌(例如:插入AOX1或his4 而不是取代AOX1)。
毕赤酵母内源蛋白表达系统发酵优化策略随着生物技术和生物医药行业的快速发展,蛋白表达成为了研究和生产领域中一个至关重要的环节。
毕赤酵母(Pichia pastoris)作为一种有效的真菌表达系统,被广泛应用于蛋白表达、酶制备等领域。
本文将从毕赤酵母内源蛋白表达系统的发酵优化策略进行探讨,以期为相关研究提供一定的参考和借鉴意义。
一、毕赤酵母内源蛋白表达系统简介毕赤酵母是一种酿酒酵母,具有真核生物和原核生物的特点,具有许多原核和真核表达系统的优点。
Pichia pastoris作为一种高效的真菌表达系统,广泛应用于蛋白质表达、酶制备、重组激素和疫苗生产、抗体工程等领域。
毕赤酵母在高密度、大规模表达的过程中具有许多优点,例如可以利用化石燃料产生的甲醇为碳源并利用氧化酶将甲醇作为能源,这使得它在蛋白质大规模表达中的应用有了很大的便利;其次methylotrophic yeast P.pastoris是一种易于操作的槽稠传播。
分泌蛋白在生成后由细胞外酶直接切割。
得到的目的蛋白质易纯化和分离。
由于其许多优点,毕赤酵母内源蛋白表达系统在生物技术和制药行业中受到极大的关注。
二、毕赤酵母内源蛋白表达系统的发酵优化策略(一)基础培养基的选择在毕赤酵母内源蛋白表达系统的发酵过程中,培养基的选择对于蛋白质的表达和纯化至关重要。
通常情况下,毕赤酵母内源蛋白表达系统常用的基础培养基包括YPG液体培养基、BMGY培养基和BMMY培养基。
其中,BMGY培养基在毕赤酵母的扩大培养和生长过程中被广泛应用,其主要成份包括酵母抽提物(yeast extract)、复合酵母粉(peptone)、甘油(glycerol)和缓冲盐溶液等。
而BMMY培养基主要用于毕赤酵母内源蛋白表达系统的诱导表达过程,其主要成份包括酵母醣(yeast extract)、蛋白胨(peptone)、抗泡剂(anti-foaming agent)以及甲醇(methanol)等。
毕赤酵母来源Kex2蛋白酶的高效表达及酶学性质研究Kex2蛋白酶是一种来源于酵母的前体加工蛋白酶,能识别并切割碱性氨基酸残基对中的羧基端肽键,在酵母的蛋白分泌途径中起关键作用,并且在真核细胞蛋白的研究中也应用广泛。
目前多用毕赤酵母(Pichia pastoris,P.pastoris)来表达Kex2蛋白酶,但有关毕赤酵母Kex2蛋白酶(PPKex2)的同源活性表达与酶学性质的研究还鲜有报道,并且Kex2蛋白酶较低的表达量导致其生产成本过高,不利于大规模的应用。
本课题利用毕赤酵母表达系统对PPKex2进行了同源表达,并研究其酶学性质,同时与酿酒酵母(Saccharomyces cerevisiae,S.cerevisiae)Kex2蛋白酶(SCKex2)进行了比较。
并采用高密度扩大发酵、截短C端序列、更换启动子和伴侣蛋白共表达等方式提高PPKex2的表达量。
主要研究成果如下所述:(1)分别从毕赤酵母和酿酒酵母基因组中获得kex2基因,将其插入到表达载体pPIC9K中,并转化毕赤酵母GS115菌株。
重组菌株经甲醇诱导表达后,结果表明PPKex2的蛋白浓度达到0.42 mg·mL<sup>-1</sup>,酶活达到30.2 U·L<sup>-1</sup>,PPKex2的发酵上清比酶活是SCKex2的7倍。
Kex2蛋白酶使用Q-FF强阴离子交换柱进行纯化并研究酶学性质。
结果表明,PPKex2的最适反应pH是8.0-9.0,最适反应温度是37oC,与SCKex2性质相近。
在稳定性方面,PPKex2在pH 7.0时最稳定,在碱性条件下的稳定性高于SCKex2,在酸性条件下的稳定性低于SCKex2,另外PPKex2的温度稳定性略低于SCKex2。
酶促反应动力学研究表明,PPKex2的k<sub>cat</sub>和k<sub>cat</sub>/K<sub>m</sub>值分别为SCKex2的4.8倍和3.3倍。
北京化工大学硕士学位论文重组表达载体pPIC9K-Hepcidin的构建及其在毕赤酵母中的表达和鉴定姓名:***申请学位级别:硕士专业:环境工程指导教师:***20050615北京化工大学硕士学位论文子。
与以往在植物19]、昆虫类Ilol、和软件动物㈣发现的抗菌多肽一样,人类Hepcidin也具有广泛的抗菌、抗真菌、抗原生动物的作用。
图1_1H印cidin的结构示意图Hepcidin基因位于人的第19号染色体上,而小鼠则位于第7号染色体上。
HeDcidin基因由三个外显予和两个内含子组成,转录后的mRNA长约为O.4kb。
其中第三个外显子编码了Hepcidm的氨基酸序列。
人、大鼠和小鼠Hepcidin的基因结构极为相似,在H印cidin基因上游,均与usF2(upstre锄stinamato巧f.accor2)基因紧密相连。
两个基因中间只有1.24kb的间隔,在这一部位存在着m盯3B,C/EB邓,和NF—KB等潜在转录调节子以及1wrA起始结合位点。
NormemBloning的分析结果显示,Hepcidin的基因在肝脏特异表达,心脏、脊髓、肺表达很少,前列腺、军丸、卵巢、小肠、结肠、肾脏和膀胱几乎没有表达[6一。
HepcidiIl作为一种抗菌多肽,损伤、感染和炎症刺激可强烈引起该基因表达的增加【12,13]。
高铁饲料饲喂的小鼠,Hepcidill基因表达也显着增加【12】。
但HepcidinmRNA没有铁反应组件(IRE),所以H印cidinⅡ皿NA随铁状态而改变的机理目前尚不十分清楚垆J。
北京化工大学硕士学位论文白的作用下被氧化为三价铁,与转铁蛋白结合后在血浆中被运输到其它组织加以利用【5】(图1.2)。
图1.2ProposedstepsinHepcidinregulationofimnhomeostasis.(上)Increasedhepatocellularofn铀5f咖iIl_bo恤dironbyT矗也(oreXposufeto1ipopolysacch撕de)leadsto(2)uptakeincreasedproduc廿0nandsecretionofHepcidin,which(兰)interactswiththeB2M椰E.T侬1re劬ltionbyREmacrop}lageduode删cryptcelIs.(生)complexandincreasesironuptal(eorC叮ptcellsdi丘色rentiateirltodaugtl々erenterocytesproF咖medtohavedecreasedexpressionofironn狮sportproteins,leadjngto(量)decreaSeddie协ryironabsorp廿on,1.3铁代谢调节除了月经,人体没有排出体内铁的生理机制。
毕赤酵母表达(pichia pastoris expression )实验手册2010-07-15 10:54:56| 分类:毕赤酵母| 标签:|字号大中小订阅一.毕赤酵母表达常用溶液及缓冲液的配制二.毕赤酵母表达的培养基配制三.主要试验环节的操作 3.1 酵母菌株的分离纯化 3.2 pPICZαA原核宿主菌TOP10F’的活化培养 3.3毕赤酵母表达的试验方法 3.4 毕赤酵母电转化方法 3.5 Pichia酵母表达直接PCR鉴定重组子的方法 3.6 毕赤酵母基因组提取方法 3.7 Mut+表型重组酵母的诱导表达实验关键词:酵母实验毕赤酵母表达 pichia pastoris expression 毕赤酵母酵母菌株大肠杆菌表达系统最突出的优点是工艺简单、产量高、周期短、生产成本低。
然而,许多蛋白质在翻译后,需经过翻译后的修饰加工,如磷酸化、糖基化、酰胺化及蛋白酶水解等过程才能转化成活性形式。
大肠杆菌缺少上述加工机制,不适合用于表达结构复杂的蛋白质。
另外,蛋白质的活性还依赖于形成正确的二硫键并折叠成高级结构,在大肠杆菌中表达的蛋白质往往不能进行正确的折叠,是以包含体状态存在。
包含体的形成虽然简化了产物的纯化,但不利于产物的活性,为了得到有活性的蛋白,就需要进行变性溶解及复性等操作,这一过程比较繁琐,同时增加了成本。
大肠杆菌是用得最多、研究最成熟的基因工程表达系统,当前已商业化的基因工程产品大多是通过大肠杆菌表达的,其主要优点是成本低、产量高、易于操作。
但大肠杆菌是原核生物,不具有真核生物的基因表达调控机制和蛋白质的加工修饰能力,其产物往住形成没有活性的包涵体,需要经过变性、复性等处理,才能应用。
近年来,以酵母作为工程菌表达外源蛋白日益引起重视,原因是与大肠杆菌相比,酵母是低等真核生物,除了具有细胞生长快,易于培养,遗传操作简单等原核生物的特点外,又具有真核生物时表达的蛋白质进行正确加工,修饰,合理的空间折叠等功能,非常有利于真核基因的表达,能有效克服大肠杆菌系统缺乏蛋白翻译后加工、修饰的不足。
Pichia Expression KitVersion M01110225-0043Pichia Expression KitA Manual of Methods for Expression of Recombinant Proteins in Pichia pastorisCatalog no. K1710-01tech_service@iiINDIVIDUAL PICHIA EXPRESSION KIT LICENSE AGREEMENTThe Pichia Expression Kit is based on the yeast Pichia pastoris. Pichia pastoris was developed into an expression system by scientists at Salk Institute Biotechnology/Industry Associates (SIBIA) for high-level expression of recombinant proteins. All patents for Pichia pastoris and licenses for its use as an expression system are owned by Research Corporation Technologies, Inc. Tucson, Arizona. Invitrogen has an exclusive license to sell the Pichia Expression Kit to scientists for research purposes only, under the terms described below. Use of Pichia pastoris by commercial corporations requires the user to obtain a commercial license as detailed below. Before using the Pichia Expression Kit, please read the following license a greement. If you do not agree to be bound by its terms, contact Invitrogen within 10 days for authorization to return the unused Pichia Expression Kit and to receive a full credit. If you do agree to the terms of this Agreement, please complete the User Registration Card and return it to Invitrogen before using the kit.INDIVIDUAL PICHIA EXPRESSION KIT LICENSE AGREEMENTInvitrogen Corporation (INVITROGEN) grants you a non-exclusive license to use the enclosed Pichia Expression Kit (EXPRESSION KIT) for academic research or for evaluation purposes only. The EXPRESSION KIT is being transferred to you in furtherance of, and reliance on, such license. You may not use the EXPRESSION KIT, or the materials contained therein, for any commercial purpose without a license for such purpose from RESEARCH CORPORATION TECHNOLOGIES, INC., Tucson, Arizona. Commercial purposes include the use in or sale of expressed proteins as a commercial product, or use to facilitate or advance research or development of a commercial product. Commercial entities may conduct their evaluation for one year at which time this license automatically terminates. Commercial entities will be contacted by Research Corporation Technologies during the evaluation period regarding the purchase of a commercial license.Access to the EXPRESSION KIT must be limited solely to those officers, employees and students of your institution who need access thereto in order to perform the above-described research or evaluation. You must inform each of such officer, employee and student of the provisions of this Agreement and require them to agree, in writing, to be bound by the provisions of this Agreement. You may not distribute the EXPRESSION KIT to others, even those within your own institution. You may transfer modified, altered or original material from the EXPRESSION KIT to a third party following notification of INVITROGEN such that the recipient can be licensed. You may not assign, sub-license, rent lease or otherwise transfer this License or any of the rights or obligation hereunder, except as expressly permitted.This License is effective until terminated. You may terminate it at any time by destroying all Pichia expression products in your control. It will also terminate automatically if you fail to comply with the terms and conditions of the Agreement. You shall, upon termination of the License, destroy all Pichia Expression Kits in your control, and so notify INVITROGEN in writing.This License Shall be governed in its interpretation and enforcement by the laws of the State of California.Product User Registration CardPlease complete and return the enclosed Product User Registration Card for each Pichia Expression Kit that you purchase. This will serve as a record of your purchase and registration and will allow Invitrogen to provide you with technical support and manual updates. It will also allow Invitrogen to update you on future developments of and improvements to the Pichia Expression Kit. The agreement outlined above becomes effective upon our receipt of your User Registration Card or 10 days following the sale of the Pichia Expression Kit to you. Use of the kit at any time results in immediate obligation to the terms and conditions stated in this Agreement.Technical ServicesInvitrogen provides Technical Services to all of our registered Pichia Expression Kit users. Please contact us if you need assistance with the Pichia Expression Kit.United States Headquarters:Japanese Headquarters European Headquarters:Invitrogen Corporation1600 Faraday AvenueCarlsbad, CA 92008 USATel: 1 760 603 7200Tel (Toll Free): 1 800 955 6288 Fax: 1 760 602 6500E-mail:tech_service@ Invitrogen Japan K.K.Nihonbashi Hama-Cho Park Bldg. 4F2-35-4, Hama-Cho, NihonbashiTel: 81 3 3663 7972Fax: 81 3 3663 8242E-mail: jpinfo@Invitrogen Ltd3 Fountain DriveInchinnan Business ParkPaisley PA4 9RF, UKTel (Free Phone Orders): 0800 269 210Tel (General Enquiries): 0800 5345 5345Fax: +44 (0) 141 814 6287E-mail: eurotech@iiiivTable of ContentsMaterials (vii)Purchaser Notification (x)Product Qualification (xii)Introduction (1)Overview (1)Experimental Outline (3)Recombination and Integration in Pichia (7)Methods (11)Pichia Strains (11)E. coli Strains (13)Selecting a Pichia Expression Vector (14)pHIL-D2 (16)pPIC3.5 (17)pHIL-S1 (18)pPIC9 (19)Signal Sequence Processing (20)Cloning into the Pichia Expression Vectors (21)Transformation into E. coli (26)Preparation of Transforming DNA (27)Growth of Pichia for Spheroplasting (30)Preparation of Spheroplasts (32)Transformation of Pichia (34)Screening for Mut+ and Mut S Transformants (36)PCR Analysis of Pichia Integrants (40)Expression of Recombinant Pichia Strains (42)Analysis by SDS-Polyacrylamide Gel Electrophoresis (45)Optimization of Pichia Protein Expression (47)Scale-up of Expression (49)Protein Purification and Glycosylation (51)Recipes (53)E. coli Media Recipes (53)Pichia Media Recipes (54)Appendix (59)Electroporation of Pichia (59)PEG 1000 Transformation Method for Pichia (60)Lithium Chloride Transformation Method (61)Total DNA Isolation from Pichia (62)Detection of Multiple Integration Events (63)Procedure for Total RNA Isolation from Pichia (64)β-Galactosidase Assay (65)Technical Service (67)References (69)vviMaterialsKit Contents Box 1: Spheroplast Module. Store at room temperature.Reagent Amount ComponentsSOS media 20 ml 1 M Sorbitol0.3X YPD10 mM CaCl2Sterile Water 2 x 125 ml Autoclaved, deionized waterSE 2 x 125 ml 1 M Sorbitol25 mM EDTA, pH 8.0SCE 2 x 125 ml 1 M Sorbitol10 mM Sodium citrate buffer, pH 5.81 mM EDTA1 M Sorbitol2 x 125 ml --CaS 2 x 60 ml 1 M Sorbitol10 mM Tris-HCl, pH 7.5;10 mM CaCl240% PEG 25 ml 40% (w/v) PEG 3350 (Reagent grade) in waterCaT 25 ml 20 mM Tris-HCl, pH 7.520 mM CaCl2Stab Vials: Pichia and E. coli stabs. Store at +4°C.Phenotype(Pichia only)GenotypeStrain Amountstab his4Mut+GS115 1stab arg4 his4 aox1::ARG4 Mut S, Arg+KM71 1GS115 Albumin 1 stab HIS4Mut SGS115 β-Gal 1 stab HIS4Mut+stab F´ {pro AB, lac I q, lac Z∆M15, Tn10 (Tet R)} mcr A,TOP10F´ 1∆(mrr-hsd RMS-mcr BC), φ80lac Z∆M15, ∆lac X74,deo R, rec A1, ara D139, ∆(ara-leu)7697, gal U,gal K, rps L (Str R), end A1, nup G λ-.Box 2: Spheroplast Module. Store at -20°C.ComponentsReagent AmountZymolyase 10 x 20 µl 3 mg/ml Zymolyase in water(100,000 units/g lytic activity)1 M DTT 10 x 1 ml 1 M dithiothreitol in watercontinued on next pageviiKit Contents,continuedVector Box. Store at -20°C.Reagent DescriptionpHIL-D210 µg, lyophilized in TE, pH 8.0Vector for intracellular expression in PichiapPIC3.510 µg, lyophilized in TE, pH 8.0Vector for intracellular expression in PichiapHIL-S110 µg, lyophilized in TE, pH 8.0 Vector for secreted expression in Pichia. Uses the PHO1 signal sequencepPIC910 µg, lyophilized in TE, pH 8.0 Vector for secreted expression in Pichia. Uses the α-factor signal sequencePrimer Box. Store at -20°C.5´ AOX1 sequencing primer2 µg (312 pmoles), lyophilized5´-GACTGGTTCCAATTGACAAGC-3´3´ AOX1 sequencing primer2 µg (314 pmoles), lyophilized5´-GCAAATGGCATTCTGACATCC-3´α-Factor sequencing primer2 µg (315 pmoles), lyophilized5´-TACTATTGCCAGCATTGCTGC-3´Media The following prepackaged media is included for your convenience. Instructions for use are provided on the package.Media Amount Yield YP Base Medium 2 pouches 2 liters of YP mediumYP Base Agar Medium 2 pouches 2 liters of YP mediumYeast Nitrogen Base 1 pouch 500 ml of 10X YNBFor transformation of Pichia by spheroplasting, the Pichia Spheroplast Module isavailable separately from Invitrogen (see below for ordering information).Product Reactions or Amount Catalog no.Pichia Spheroplast Module 10 spheroplast preparations(50 transformations)K1720-01continued on next pageviiiRequired Equip-ment and Supplies (not provided) • 30°C rotary shaking incubator• Water baths capable of 37°C, 45°C, and 100°C• Centrifuge suitable for 50 ml conical tubes (floor or table-top)• Baffled culture flasks with metal covers (50 ml, 250 ml, 500 ml, 1000 ml, and 3 L)• 50 ml sterile, conical tubes• 6 ml and 15 ml sterile snap-top tubes (Falcon 2059 or similar)• UVSpectrophotometer• Mini agarose gel apparatus and buffers• Polyacrylamide Gel Electrophoresis apparatus and buffers• Media for transformation, growth, screening, and expression (see Recipes, pages 53-58) • 5% SDS solution (10 ml per transformation)• Sterile cheesecloth or gauze• Breaking Buffer (see Recipes, page 58)• Acid-washed glass beads (available from Sigma)• Replica-plating equipment (optional)• BeadBreaker™ (optional)ixPurchaser NotificationIntroduction The Pichia Expression Kit is based on the yeast Pichia pastoris. Pichia pastoris wasdeveloped into an expression system by scientists at Salk Institute Biotechnology/ IndustryAssociates (SIBIA) and Phillips Petroleum for high-level expression of recombinantproteins. All patents for Pichia pastoris and licenses for its use as an expression system areowned by Research Corporation Technologies (RCT), Inc., Tucson, Arizona. Forinformation on commercial licenses, please see page x.The Nature of the Invitrogen License Invitrogen has an exclusive license to sell the Pichia Expression Kit to scientists for research purposes only, under the terms described below. Use of Pichia pastoris by commercial entities for any commercial purpose requires the user to obtain a commercial license as detailed below. Before using the Pichia Expression Kit, please read the following license agreement. If you do not agree to be bound by its terms, contact Invitrogen within 10 days for authorization to return the unused Pichia Expression Kit and to receive a full credit. If you do agree to the terms of this license agreement, please complete the User Registration Card and return it to Invitrogen before using the kit.Pichia pastoris Patents Pichia pastoris is covered by one or more of the following U.S. patents and corresponding foreign patents owned and licensed by Research Corporation Technologies:4,683,293 4,808,537 4,812,405 4,818,700 4,837,148 4,855,231 4,857,467 4,879,231 4,882,279 4,885,242 4,895,800 4,929,555 5,002,876 5,004,688 5,032,516 5,122,465 5,135,868 5,166,329Individual Pichia Expression Kit License Agreement Invitrogen Corporation ("Invitrogen") grants you a non-exclusive license to use the enclosed Pichia Expression Kit ("Expression Kit") for academic research or for evaluation purposes only. The Expression Kit is being transferred to you in furtherance of, and reliance on, such license. You may not use the Expression Kit, or the materials contained therein, for any commercial purpose without a license for such purpose from Research Corporation Technologies, Inc., Tucson, Arizona.Definition of Commercial Purpose Commercial purposes include:(a) any use of Expression Products in a Commercial Product(b) any use of Expression Products in the manufacture of a Commercial Product(c) any sale of Expression Products(d) any use of Expression Products or the Expression Kit to facilitate or advanceresearch or development of a Commercial Product(e) any use of Expression Products or the Expression Kit to facilitate or advance anyresearch or development program the results of which will be applied to thedevelopment of Commercial Products"Expression Products" means products expressed with the Expression Kit, or with the use of any vectors or host strains in the Expression Kit. "Commercial Product" means any product intended for sale or commercial use.Commercial entities may conduct their evaluation for one year at which time this license automatically terminates. Research Corporation Technologies will contact commercial entities during the evaluation period regarding their desire for a commercial license.continued on next pagexPurchaser Notification, continuedIndividual Responsibilities Access to the Expression Kit must be limited solely to those officers, employees and students of your institution who need access to perform the above-described research or evaluation. You must inform each such officer, employee and student of the provisions of this license agreement and require them to agree, in writing, to be bound by the provisions of this license agreement. You may not distribute neither the Expression Kit nor the vectors or host strains contained in it to others, even to those within your own institution. You may only transfer modified, altered, or original material from the Expression Kit to a third party following written notification of, and written approval from, Invitrogen so that the recipient can be licensed. You may not assign, sub-license, rent, lease or otherwise transfer this license agreement or any of the rights or obligation thereunder, except as expressly permitted by Invitrogen and RCT.Termination of License This license agreement is effective until terminated. You may terminate it at any time by destroying all Pichia expression products in your control. It will also terminate auto-matically if you fail to comply with the terms and conditions of the license agreement. You shall, upon termination of the license agreement, destroy all Pichia Expression Kits in your control, and so notify Invitrogen in writing.This License shall be governed in its interpretation and enforcement by the laws of the State of California.Contact for Commercial Licensing Bennett Cohen, Ph.D.Research Corporation Technologies 101 North Wilmot Road, Suite 600 Tucson, Arizona 85711-3335 Phone: (520) 748-4400Fax: (520)748-0025User Registration Card Please complete and return the enclosed User Registration Card for each PichiaExpression Kit that you purchase. This will serve as a record of your purchase and regis-tration and will allow Invitrogen to provide you with technical support and manualupdates. It will also allow Invitrogen to update you on future developments and improve-ments to the Pichia Expression Kit. The agreement outlined above becomes effectiveupon our receipt of your User Registration Card or 10 days following the sale of thePichia Expression Kit to you. Use of the kit at any time results in immediate obligation tothe terms and conditions stated in this license agreement.xiProduct QualificationIntroduction This section describes the criteria used to qualify the components in the PichiaExpression Kit.Vectors All expression vectors are qualified by restriction enzyme digestion. Restriction digests must demonstrate the correct banding pattern when electrophoresed on an agarose gel.Spheroplast Reagents The spheroplast reagents are qualified by spheroplast preparation of GS115 following the protocol provided in the Pichia Expression Kit manual. At least 70% of the Pichia pastoris cells must form spheroplasts in 30 minutes or less.Pichia Strains The Pichia strains are by demonstrating viability of the culture. Single colonies should arise within 48 hours after streaking on YPD medium from the stabPrimers Sequencing primers are lot tested by automated DNA sequencing experiments.Buffers andSolutionsAll buffers and solutions are extensively tested for sterility.Media All Pichia growth and expression media are qualified by growing the GS115 Pichiastrain.xiiIntroductionOverviewReview Articles The information presented here is designed to give you a concise overview of the Pichia pastoris expression system. It is by no means exhaustive. For further information, pleaseread the articles cited in the text along with recent review articles (Buckholz and Gleeson,1991; Cregg et al., 1993; Sreekrishna et al., 1988; Wegner, 1990). A general review offoreign gene expression in yeast is also available (Romanos et al., 1992).General Characteristics of Pichia pastoris As a eukaryote, Pichia pastoris has many of the advantages of higher eukaryotic expression systems such as protein processing, protein folding, and posttranslational modification, while being as easy to manipulate as E. coli or Saccharomyces cerevisiae. It is faster, easier, and less expensive to use than other eukaryotic expression systems such as baculovirus or mammalian tissue culture, and generally gives higher expression levels. As a yeast, it shares the advantages of molecular and genetic manipulations with Saccharomyces, and has the added advantage of 10- to 100-fold higher heterologous protein expression levels. These features make Pichia very useful as a protein expression system.Similarity to Saccharomyces Many of the techniques developed for Saccharomyces may be applied to Pichia including: • transformation by complementation• genedisruption• genereplacementIn addition, the genetic nomenclature used for Saccharomyces has been applied to Pichia. For example, the HIS4 gene in both Saccharomyces and Pichia encodes histidinol dehydrogenase. There is also cross-complementation between gene products in both Saccharomyces and Pichia. Several wild-type genes from Saccharomyces complement comparable mutant genes in Pichia. Genes such as HIS4, LEU2, ARG4, TRP1, and URA3 all complement their respective mutant genes in Pichia.Pichia pastoris as a Methylotrophic Yeast Pichia pastoris is a methylotrophic yeast, capable of metabolizing methanol as its sole carbon source. The first step in the metabolism of methanol is the oxidation of methanol to formaldehyde using molecular oxygen by the enzyme alcohol oxidase. This reaction generates both formaldehyde and hydrogen peroxide. To avoid hydrogen peroxide toxicity, methanol metabolism takes place within a specialized cell organelle called the peroxisome, which sequesters toxic by-products from the rest of the cell. Alcohol oxidase has a poor affinity for O2, and Pichia pastoris compensates by generating large amounts of the enzyme. The promoter regulating the production of alcohol oxidase drives heterologous protein expression in Pichia.Two Alcohol Oxidase Proteins The AOX1 and AOX2 genes code for alcohol oxidase in Pichia pastoris. The AOX1 gene product accounts for the majority of alcohol oxidase activity in the cell. Expression of the AOX1 gene is tightly regulated and induced by methanol to high levels, typically > 30% ofthe total soluble protein in cells grown with methanol as the carbon source. The AOX1 gene has been isolated and the AOX1 promoter is used to drive expression of the gene of interest (Ellis et al., 1985; Koutz et al., 1989; Tschopp et al., 1987a). While AOX2 is about 97% homologous to AOX1, growth on methanol is much slower than with AOX1. This slowgrowth allows isolation of Mut S strains (aox1) (Cregg et al., 1989; Koutz et al., 1989).continued on next page1Overview, continuedExpression Expression of the AOX1 gene is controlled at the level of transcription. In methanol-grown cells approximately 5% of the polyA+ RNA is from the AOX1 gene. The regulation of theAOX1 gene is a two step process: a repression/derepression mechanism plus an inductionmechanism (e.g. GAL1 gene in Saccharomyces (Johnston, 1987)). Briefly, growth onglucose represses transcription, even in the presence of the inducer methanol. For thisreason, growth on glycerol is recommended for optimal induction with methanol. Pleasenote that growth on glycerol (derepression) is not sufficient to generate even minute levelsof expression from the AOX1 gene. The inducer, methanol, is necessary for detectablelevels of AOX1 expression (Ellis et al., 1985; Koutz et al., 1989; Tschopp et al., 1987a).Phenotype of aox1 mutants Loss of the AOX1 gene, and thus a loss of most of the cell's alcohol oxidase activity, results in a strain that is phenotypically Mut S (Methanol utilization slow). This has in the past been referred to as Mut. The Mut S designation has been chosen to accurately describe the phenotype of these mutants. This results in a reduction in the cells' ability to metabolize methanol. The cells, therefore, exhibit poor growth on methanol medium. Mut+ (Methanol utilization plus) refers to the wild type ability of strains to metabolize methanol as the sole carbon source. These two phenotypes are used when evaluating Pichia transformants for integration of your gene (Experimental Outline, page 3).Intracellular and Secretory Protein Expression Heterologous expression in Pichia can be either intracellular or secreted. Secretion requires the presence of a signal sequence on the expressed protein to target it to the secretory pathway. While several different secretion signal sequences have been used successfully, including the native secretion signal present on some heterologous proteins, success has been variable. The secretion signal sequence from the Saccharomyces cerevisiaeα factor prepro peptide has been used most successfully (Cregg et al., 1993; Scorer et al., 1993).The major advantage of expressing heterologous proteins as secreted proteins is that Pichia pastoris secretes very low levels of native proteins. That, combined with the very low amount of protein in the minimal Pichia growth medium, means that the secreted heterologous protein comprises the vast majority of the total protein in the medium and serves as the first step in purification of the protein (Barr et al., 1992). Note: If there are recognized glycosylation sites (Asn-X-Ser/Thr) in your protein's primary sequence, glycosylation may occur at these sites.Posttranslational Modifications In comparison to Saccharomyces cerevisiae, Pichia may have an advantage in the glyco-sylation of secreted proteins because it may not hyperglycosylate. Both Saccharomyces cerevisiae and Pichia pastoris have a majority of N-linked glycosylation of the high-mannose type; however, the length of the oligosaccharide chains added posttranslationally to proteins in Pichia (average 8-14 mannose residues per side chain) is much shorter than those in S. cerevisiae (50-150 mannose residues) (Grinna and Tschopp, 1989; Tschopp et al., 1987b). Very little O-linked glycosylation has been observed in Pichia.In addition, Saccharomyces cerevisiae core oligosaccharides have terminal α1,3 glycan linkages whereas Pichia pastoris does not. It is believed that the α1,3 glycan linkages in glycosylated proteins produced from Saccharomyces cerevisiae are primarily responsible for the hyper-antigenic nature of these proteins making them particularly unsuitable for therapeutic use. Although not proven, this is predicted to be less of a problem for glycoproteins generated in Pichia pastoris, because it may resemble the glycoprotein structure of higher eukaryotes (Cregg et al., 1993).2Experimental OutlineSelection of Vector and Cloning To utilize the strong, highly inducible P AOX1 promoter for expression of your protein, four expression vectors are included in this kit. pHIL-D2 and pPIC3.5 are used for intracellular expression while pHIL-S1 and pPIC9 are used for secreted expression (see pages 14-19 for more information). Before cloning your insert, you must...• decide whether you want intracellular or secreted expression.• analyze your insert for the following restriction sites: Sac I, Stu I, Sal I, Not I, and Bgl II. These sites are recommended for linearizing your construct prior to Pichiatransformation. If your insert has all of these sites, see pages 28-29 for alternate sites.Transformation and IntegrationTwo different phenotypic classes of His+ recombinant strains can be generated: Mut+ and Mut S. Mut S refers to the "Methanol utilization slow" phenotype caused by the loss of alcohol oxidase activity encoded by the AOX1 gene. A strain with a Mut S phenotype has a mutant aox1 locus, but is wild type for AOX2. This results in a slow growth phenotype on methanol medium. Transformation of strain GS115 can yield both classes of transformants, His+ Mut+ and His+Mut S, while KM71 yields only His+ Mut S since the strain itself is Mut S. Both Mut+ and Mut S recombinants are useful to have as one phenotype may favor better expression of your protein than the other. Due to clonal variation, you should test 6-10 recombinants per phenotype. There is no way to predict beforehand which construct or isolate will better express your protein. We strongly recommend that you analyze Pichia recombinants by PCR to confirm integration of your construct (see page 40).Once you have successfully cloned your gene, you will then linearize your plasmid to stimulate recombination when the plasmid is transformed into Pichia. The table below describes the types of recombinants you will get by selective digestion of your plasmid. RestrictionEnzymeIntegration Event GS115 Phenotype KM71 PhenotypeSal I or Stu I Insertion at his4His+ Mut+ His+ Mut SSac I Insertion at 5´AOX1 regionHis+ Mut+ His+ Mut SNot I or Bgl II Replacement atAOX1 locusHis+ Mut SHis+ Mut+His+ Mut S (notrecommended, see page 11)Expression and Scale-up After confirming your Pichia recombinants by PCR, you will test expression of both His+Mut+ and His+ Mut S recombinants. This will involve growing a small culture of each recombinant, inducing with methanol, and taking time points. If looking for intracellular expression, analyze the cell pellet from each time point by SDS polyacrylamide gel electrophoresis (SDS-PAGE). If looking for secreted expression, analyze both the cellpellet and supernatant from each time point. We recommend that you analyze your SDS-PAGE gels by both Coomassie staining and Western blot, if you have an antibody to your protein. We also suggest checking for protein activity by assay, if one is available. Not all proteins express to the level of grams per liter, so it is advisable to check by Western blotor activity assay, and not just by Coomassie staining of SDS-PAGE gels for production of your protein.Choose the Pichia recombinant strain that best expresses your protein and optimizeinduction based on the suggestions on pages 47-48. Once expression is optimized, scale-up your expression protocol to produce more protein.continued on next page3。
毕赤酵母组成型高效表达启动子的筛选鉴定石义超;王凤忠;江均平;朱利泉【摘要】为获得高产量、高活性的葡萄糖氧化酶(GOD)酵母表达菌株,优化了GOD的T132S/T56V双突变编码序列,将之克隆到表达载体pGAPk上得到表达载体pGAPk-h2-GOD,以pGAP启动GOD基因的表达.将pGAPk-h2-GOD上的pGAP启动子替换为pGCW14和pAOX1,并对pGCW14启动子进行改造,得到3种pGCW14的改造体,最终得到包括pGAPk-h2-GOD在内的6种不同启动子的重组表达载体.将这6种载体转化毕赤酵母GS115,建立了一种简便高效的筛选方法初步筛选出GOD重组菌株,再对筛选到的转化子进行发酵培养,测定发酵上清液的GOD酶活力,以此来比较各种启动子启动效率的强弱.结果显示:pGCW14的启动效率是pGAP的3~5倍,改造后的启动子pGCW14+ G20A/C-467T(0.767)和pGCW14-UA(0.689)的启动效率较原始的pGCW14(0.574)都有明显的提高,尤其pGCW14+ G20A/C-467T启动效率最高,比原始pGCW14提高了32.5%左右.与诱导型启动子pAOX1 (1.187)相比,pGCW14+ G20A/C-467T(1.109)的启动效率仅比其低6.6%左右.结论:改造后的启动子可望在毕赤酵母组成型高效表达的研究应用中具有一定的前景.【期刊名称】《食品工业科技》【年(卷),期】2018(039)013【总页数】7页(P110-116)【关键词】葡萄糖氧化酶;巴氏毕赤酵母;启动子pGCW14;组成型表达【作者】石义超;王凤忠;江均平;朱利泉【作者单位】西南大学农学与生物科技学院,重庆400715;中国农业科学院农产品加工研究所,北京100193;中国农业科学院农产品加工研究所,北京100193;西南大学农学与生物科技学院,重庆400715【正文语种】中文【中图分类】TS201.3随着基因工程技术和蛋白异源表达的飞速发展,越来越多的表达系统被建立并得到广泛应用。
-毕赤酵母高效表达策略概述1.基因的内在特性主要包括mRNA 5’端非翻译区(5’2 U TR)、基因的A +T 组成和密码子的使用频率3 个方面。
由于巴斯德毕赤酵母中乙醇氧化酶的表达量极高(占胞内可溶蛋白的30% 以上) 因此为了有高的蛋白表达量,维持外源基因mRNA 5’-U TR。
尽可能和AOXlmRNA 5’-U TR 相似是必需的, 最好是保持两者一致。
A + T 含量高的基因在巴斯德毕赤酵母中表达时偶尔会造成转录提前终止,这是因为A T 丰富区可能存在转录提前终止信号。
因此对A T 含量丰富的基因最好是重新设计序列, 使其A + T 含量在30%~55% 范围内。
巴斯德毕赤酵母也有特殊的密码子偏好趋向。
(赵翔,霍克克,李育阳. 毕赤酵母的密码子用法分析[J ] . 生物工程学报,2000 ,16(3) :308 - 311.)外源蛋白自身的理化特点也影响其表达和分泌。
外源蛋白的加工修饰都会影响蛋白的表达量。
2.选择强启动子启动子在转录水平上调控基因的表达最常用的启动子是AOXI 启动子。
PGAG(三磷酸甘油醛脱氢酶启动子) 是最近在巴斯德毕赤酵母中克隆到的一个组成型启动子,在它的控制下β- LabZ 基因表达率比甲醇诱导下的PAOX驱动的产量更高,由于该组成型启动子不需要甲醇诱导,发酵工艺应该更简单,同时其产量更高,所以成为代替PAOX1 最有潜力的启动子。
通过分离选择恢复利用甲醇能力的自发突变体, 从AOX1 基因缺陷菌株中分离M ut+ 的自发突变体,从中筛选提高表达量的突变体。
(戴秀玉, 王恂, 周坚1毕赤氏酵母PAOX2 突变化序列分析〔J 〕1微生物学报, 1999, 39 (6) :559~5611)3.增加外源基因整合拷贝数(1)Invitrogen 公司最新发展的质粒pPIC9K上带有G418 的抗性基因,可以通过转化子对G418抗性水平快速筛选高拷贝转化子(配合电激法转化的效果更好)。